X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The award will be used for the development and preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain, utilizing the body’s endogenous pain controllers, the enkephalins.
Lead Product(s): IC 800
Therapeutic Area: Ophthalmology Product Name: IC 800
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: U.S. Army Medical Research Acquisition Activity
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 28, 2021
Details:
Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 and other DENKI drugs from Pharmaleads’ portfolio.
Lead Product(s): IC 800
Therapeutic Area: Ophthalmology Product Name: IC 800
Highest Development Status: IND EnablingProduct Type: Undisclosed
Recipient: Pharmaleads
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 07, 2021
Details:
The exclusive license is for ophthalmic indications in China and other countries of Southeast Asia. The agreement will accelerate the development of IC 265 and IC 270 in both China and the U.S.
Lead Product(s): IC 265
Therapeutic Area: Ophthalmology Product Name: IC 265
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Ophthalmology Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
